Diagnosis and management of dilated cardiomyopathy

Heart

Volumn 84, Issue 1, 2000, Pages 106-112

  Elliott, Perry ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARNITINE DEFICIENCY; HEART DILATATION; HUMAN; MYOCARDITIS; PHENOTYPE; PRIORITY JOURNAL; SELENIUM DEFICIENCY; ADULT; BIOPSY; CONGESTIVE CARDIOMYOPATHY; DRUG ANTAGONISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART MUSCLE; HEART PACING; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY; PRESCHOOL CHILD; REVIEW; VIRUS INFECTION;

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, DILATED; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MYOCARDIUM; RECEPTORS, ANGIOTENSIN; SPIRONOLACTONE; VIRUS DISEASES;

EID: 0034220604     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mestroni L, Maisch B, McKenna WJ, et al. Collaborative research group of the European human and capital mobility project on familial dilated cardiomyopathy. Guidelines for the study of familial dilated cardiomyopathies. Eur Heart J 1999;20:93-102. The inherited nature of IDC is often overlooked in the management of patients with IDC. This paper provides a set of practical guidelines for the clinical diagnosis of gene carriers.
2. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997;78:539-43. This review discusses some of the potential reasons for the wide range of estimates for viral infection in patients with IDC. In many cases methodological considerations are just as important as genuine variation in the incidence of viral infection.
3. Noutsias M, Seeberg B, Schultheiss H-P, et al. Expression of cell adhesion molecules in dilated cardiomyopathy. Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999;99:2124-31. The identification of immune activation in patients with IDC is likely to be of increasing importance in the diagnosis of disease in patients and their relatives. In particular it may help to identify patients who might benefit from immunomodulatory treatments.
4. European Society of Cardiology. The treatment of heart failure The task force of the working group on heart failure of the European Society of Cardiology. Eur Heart J 1997;18:736-53. General review and guidelines for the management of congestive cardiac failure. These guidelines do not take into account recent data on β blockers, All receptor antagonists, and spironolactone.
5. Packer M, Poole-Wilson P, Armstrong P, et al. The ATLAS study group 1. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312. This paper shows that high dose ACE inhibitor treatment is superior to low dose with regard to hospitalisation rates for heart failure. The study did not evaluate moderate doses, but the paper provides clear evidence that it is desirable to aim as close as possible to maximum recommended doses of ACE inhibitors in heart failure patients.
6. Pitt B, Segal R, Martinez F, Meurers G, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52. First large study to demonstrate that angiotensin II antagonists are tolerated at least as well as ACE inhibitors. The trial also suggested that mortality was lower in the losartan group, but the trial was not powered to make this observation.
7. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive cardiac failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 1999;100:1056-64. This study suggests that the combination of an ACE inhibitor and an All receptor antagonist may be more effective than either agent alone in reducing neurohumoral activation and in preventing ventricular remodelling. Large scale trials are now underway to investigate this hypothesis.
8. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure US carvedilol heart failure study group. N Engl J Med 1996;334:1349-55. Although this study was in fact a composite of four smaller studies, the results of carvedilol treatment were impressive with a dramatic 65% reduction in mortality risk and a 38% reduction in the risk of death or hospitalisation. Similar reductions in mortality have now been observed with metoprolol and bisoprolol.
9. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. This study enrolled 2647 patients with stable class III/IV symptoms and ejection fraction less than 0.35. Bisoprolol treatment (target dose 10 mg) was associated with a mortality rate of 11.8% compared to 17.3% in the placebo arm.
10. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7. This study enrolled 3911 patients with stable class II-IV symptoms and ejection fraction less than 0.40. Mortality in the 1990 patients that received metoprolol CR/XL (target dose 200 mg) was 7.2% compared to 11% (p = 0.00009).
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17. First large scale study to show that aldosterone antagonism in patients with class III/IV symptoms already taking ACE inhibitors is associated with a substantial reduction in mortality. The benefit occurred with low dose treatment, without a high incidence of hyperkalaemia.
12. Sliwa K, Skudicky, Candy G, et al. Randomised investigation of effects of pentoxifylline on left ventricular performance in idiopathic cardiomyopathy. Lancet 1998;351:1091-3. Placebo controlled double blind study of 28 patients with idiopathic dilated cardiomyopathy. Treatment with pentoxifylline, an inhibitor of TNFα production, was associated with improvement in functional class, election fraction, and a reduction in TNFα concentrations.
13. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6. Etanercept is a soluble P75 TNFα receptor fusion protein that binds to and inactivates circulating TNFα. In this study a single intravenous infusion resulted in improvement or six minute walk, ejection fraction, and quality of life score for two weeks. Etanercept is now being studied in large scale multicentre studies.
14. Dovai H, Nul D, Grancelli H, et al. Gruppo de Estudio de la Sobrevida en la Insuficiencia en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8. In this study, 516 patients with congestive cardiac failure were randomised to either placebo or amiodarone 300 mg daily. Amiodarone was associated with a 28% reduction in relative risk. Only 12 patients had to discontinue the drug because of side effects.
15. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. Circulation 1996;93:2128-34. In this study, 674 patients with class II-IV heart failure were randomised in a double blind fashion to either amiodarone or placebo. Amiodarone was associated with an improvement in ejection fraction, and a significant reduction in the composite end point of hospitalisation and cardiac death in patients with non-ischaemic heart failure. Compared to GESICA, many more patients in this study were withdrawn from treatment because of side effects. The difference in outcome may be explained by many factors including inclusion criteria, sex differences, prevalence of non-sustained ventricular tachycardia, and the aetiology and severity of heart failure.
16. Torp-Pedersen C, Moller M, Bloch-Thomsen P, et al. The Danish investigations of arrhythmia and mortality on dofetilide study group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-65. This study demonstrates that dofetilide, a novel class III antiarrhythmic drug, is effective in reducing the incidence of atrial fibrillation in patients with congestive cardiac failure. The drug is limited by the requirement for in-hospital initiation of treatment in order to monitor for QT prolongation and torsades de pointes ventricular tachycardia.
17. McCarthy JF, McCarthy PM, Starling RC, et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive cardiac failure. Eur J Cardiothorac Surg 1998;13:337-43. In this study 57 patients, 95% of whom had IDC and were listed for transplantation, underwent partial left ventriculectomy, together with mitral valve repair in 55 patients. Seventeen patients required left ventricular assist device rescue and only 50% were free from death or transplantation at one year. Seven patients died late after surgery.
18. Rose EA, et al. The REMATCH trial: rationale, design, and end-points. Ann Thorac Surg 1999;67:723-30. This paper outlines the rationale behind the REMATCH study. In particular it discusses the difficulties in adapting the now commonplace clinical trial model used in heart failure trials to the evaluation of surgical treatments.
19. Auricchio A, Stellbrink C, Block M, et al for the Pacing Therapies for Congestive Heart Failure Study Group. The guidant heart failure research group. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-3001. Study demonstrating the beneficial effects of biventricular pacing in patients with heart failure. The major predictor of success is QRS duration.
20. McNamara D, Rosenblum W, Janosko K, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997;95:2476-8. In this study, high dose immunoglobulin was given to 10 adults hospitalised with class III/IV heart failure. Of the nine patients that left hospital there was an improvement in functional class and ejection fraction. This was not a randomised trial and requires evaluation in a large scale randomised study.